• Akari enrols seven out of nine patients in bullous pemphigoid trial

  Akari Therapeutics’ Phase II trial investigating Coversin (nomacopan) in mild-to-moderate bullous pemphigoid has so far...
  Read More...

• Cassiopea’s Winlevi uptake in acne driven by new mechanism though interest to wane

  While Cassiopea’s Winlevi (clascoterone) is likely to be FDA approved in moderate-to-severe acne, it is...
  Read More...

• AstraZeneca’s Imfinzi falls at another hurdle in non-small cell lung cancer trial

  Last week, AstraZeneca announced that its combination of Imfinzi (durvalumab) and the experimental drug tremelimumab...
  Read More...

• The most researched drugs in cystic fibrosis trials

  GlobalData analysed the number of clinical trials examining cystic fibrosis with start dates between January...
  Read More...

• Improved clinical efficacy found wanting in Phase III IMPALA trial

  This key finding has shaped the future direction for the drug as Mologen AG has...
  Read More...

• New, efficacious options offer hope for Ebola treatment and containment

  While there are currently no therapeutic options for Ebola, preliminary data from a clinical trial...
  Read More...

• Genkyotex to launch Phase II pulmonary fibrosis trial in US

  French biopharmaceutical firm Genkyotex has secured US regulatory approval to conduct a Phase II clinical...
  Read More...

• Janssen to trial mosaic-based HIV-1 preventive vaccine

  Janssen Vaccines & Prevention, a Johnson & Johnson unit, along with a consortium of partners...
  Read More...

• GSK’s Zejula meets primary goal in Phase III ovarian cancer trial

  GlaxoSmithKline (GSK) has announced promising data for its Zejula (niraparib) drug as a maintenance therapy...
  Read More...

• Trials data suggests Cosentyx from Novartis will change psoriasis market

  Cosentyx is set to change the landscape of the psoriasis market following results published by...
  Read More...